| Identification | Back Directory | [Name]
GW810781 | [CAS]
280571-30-4 | [Synonyms]
S-1360
GW810781
GSK-S-1360
1-[5-(4-Fluorobenzyl)furan-2-yl]-3-hydroxy-3-(1H-1,2,4-triazol-3-yl)propene
2-Propen-1-one, 1-[5-[(4-fluorophenyl)methyl]-2-furanyl]-3-hydroxy-3-(1H-1,2,4-triazol-3-yl)-
(Z)-1-[5-[(4-fluorophenyl)methyl]-2-furyl]-3-hydroxy-3-(2H-1,2,4-triazol-3-yl)prop-2-en-1-one
2-Propen-1-one, 1-[5-[(4-fluorophenyl)Methyl]-2-furanyl]-3-hydroxy-3-(1H-1,2,4-triazol-5-yl)- | [Molecular Formula]
C16H12FN3O3 | [MDL Number]
MFCD18642598 | [MOL File]
280571-30-4.mol | [Molecular Weight]
313.28 |
| Chemical Properties | Back Directory | [Melting point ]
178-179 °C (decomp)(Solvent: Ethyl acetate) | [Boiling point ]
529.638±60.00 °C(Press: 760.00 Torr)(predicted) | [density ]
1.412±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [pka]
8.138±0.60(predicted) |
| Hazard Information | Back Directory | [Uses]
S 1360 is a potent and selective inhibitor of HIV-1 integrase. S 1360 inhibits the catalytic activity of purified integrase (
IC50: 20 nM). The EC50, and CC50 of S 1360
in MTT assay (MT-4 cells infected with HIV-1 IIIB) are 200 nM and 12 μM, respectively. S 1360 has antiviral activity against both X4 tropic and R5 tropic strains, as well as NRTI, NNRTI and PI drug-resistant variants[1]. | [References]
[1] Neamati N. Patented small molecule inhibitors of HIV-1 integrase: a 10-year saga[J]. Expert Opinion on Therapeutic Patents, 2002, 12(5): 709-724. |
|
|